Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study
Table 3
History of curative treatment according to the major palliative treatment or BSC‡ received.
History of curative treatment
Previous curative treatment
No curative treatment (de novo IAT stage† at HCC diagnosis)
Undetermined
Total
3,205 (16.3%)
1,3512 (68.8%)
2,932 (14.9%)
19,649 (100%)
Major palliative treatment or BSC only received since the IAT stage diagnosis
TACE
1,398 (43.6%)
3,151 (23.3%)
259 (8.8%)
4,808 (24.5%)
TARE
55 (1.7%)
240 (1.8%)
11 (0.4%)
306 (1.6%)
Systemic treatment
867 (27.1%)
2,493 (18.5%)
591 (20.2%)
3,951 (20.1%)
BSC‡
885 (27.6%)
7,628 (56.5%)
2,071 (70.6%)
10,584 (53.9%)
†IAT stage: intermediate, advanced, or terminal stage; ‡best supportive care.
